JP7576754B2 - 幹細胞移植のための組成物および方法 - Google Patents

幹細胞移植のための組成物および方法 Download PDF

Info

Publication number
JP7576754B2
JP7576754B2 JP2020555511A JP2020555511A JP7576754B2 JP 7576754 B2 JP7576754 B2 JP 7576754B2 JP 2020555511 A JP2020555511 A JP 2020555511A JP 2020555511 A JP2020555511 A JP 2020555511A JP 7576754 B2 JP7576754 B2 JP 7576754B2
Authority
JP
Japan
Prior art keywords
cells
cell population
gene
enriched cell
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020555511A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019200167A5 (https=
JP2021521180A5 (https=
JP2021521180A (ja
Inventor
ブライアン ビアード
ナバーロ フリアン セビラ
ゴーラヴ シャー
キンナリー パテル
ラジ プラバカール
Original Assignee
スペースクラフト セブン リミテッド ライアビリティ カンパニー
フンダシオン パラ ラ インベスティガシオン バイオメディカ デル オスピタル インファンティル ウニベルシタリオ ニーニョ ヘスス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スペースクラフト セブン リミテッド ライアビリティ カンパニー, フンダシオン パラ ラ インベスティガシオン バイオメディカ デル オスピタル インファンティル ウニベルシタリオ ニーニョ ヘスス filed Critical スペースクラフト セブン リミテッド ライアビリティ カンパニー
Publication of JP2021521180A publication Critical patent/JP2021521180A/ja
Publication of JPWO2019200167A5 publication Critical patent/JPWO2019200167A5/ja
Publication of JP2021521180A5 publication Critical patent/JP2021521180A5/ja
Priority to JP2024176845A priority Critical patent/JP2025004171A/ja
Application granted granted Critical
Publication of JP7576754B2 publication Critical patent/JP7576754B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020555511A 2018-04-11 2019-04-11 幹細胞移植のための組成物および方法 Active JP7576754B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024176845A JP2025004171A (ja) 2018-04-11 2024-10-09 幹細胞移植のための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862656292P 2018-04-11 2018-04-11
US62/656,292 2018-04-11
PCT/US2019/027083 WO2019200167A1 (en) 2018-04-11 2019-04-11 Compositions and methods for stem cell transplant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024176845A Division JP2025004171A (ja) 2018-04-11 2024-10-09 幹細胞移植のための組成物および方法

Publications (4)

Publication Number Publication Date
JP2021521180A JP2021521180A (ja) 2021-08-26
JPWO2019200167A5 JPWO2019200167A5 (https=) 2022-04-19
JP2021521180A5 JP2021521180A5 (https=) 2022-04-19
JP7576754B2 true JP7576754B2 (ja) 2024-11-01

Family

ID=68162990

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020555511A Active JP7576754B2 (ja) 2018-04-11 2019-04-11 幹細胞移植のための組成物および方法
JP2024176845A Pending JP2025004171A (ja) 2018-04-11 2024-10-09 幹細胞移植のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024176845A Pending JP2025004171A (ja) 2018-04-11 2024-10-09 幹細胞移植のための組成物および方法

Country Status (11)

Country Link
US (1) US12539316B2 (https=)
JP (2) JP7576754B2 (https=)
KR (1) KR20210003738A (https=)
CN (1) CN112153973A (https=)
AU (2) AU2019252662A1 (https=)
BR (1) BR112020020841A2 (https=)
CA (1) CA3093708A1 (https=)
IL (2) IL307996A (https=)
MX (1) MX2020010718A (https=)
SG (1) SG11202008400SA (https=)
WO (1) WO2019200167A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3021572A1 (en) 2016-04-20 2017-10-26 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Compositions and methods for enhanced gene expression of pklr
EP3697452A4 (en) 2017-10-16 2021-11-24 Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, O.A., M.P. LENTIVIRAL VECTORS FOR ADMINISTRATION OF PKLR TO TREAT PYRUVATE KINASE DEFECTS
BR112020020841A2 (pt) 2018-04-11 2021-01-19 Fundacion Para La Investigacion Biomedica Del Hospital Infantil Universitario Nino Jesus Composições e métodos para transplante de célulastronco
CA3096293A1 (en) 2018-04-27 2019-10-31 Rocket Pharmaceuticals, Ltd. Gene therapy for cns degeneration
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
JP2023538519A (ja) 2020-08-07 2023-09-08 スペースクラフト セブン リミテッド ライアビリティ カンパニー Ａａｖベクターを使用したプラコフィリン－２（ｐｋｐ２）遺伝子治療
WO2022147347A1 (en) * 2020-12-31 2022-07-07 Vor Biopharma Inc. Compositions and methods for cd34 gene modification
WO2023183909A2 (en) * 2022-03-25 2023-09-28 Modernatx, Inc. Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016118780A1 (en) 2015-01-21 2016-07-28 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
WO2018049273A1 (en) 2016-09-08 2018-03-15 Centro De Investigaciones Energeticas Medioambientales Y Tecnologicas Gene therapy for patients with fanconi anemia

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0377676B1 (en) 1987-09-17 1995-05-24 Massachusetts Institute Of Technology Human erythroid-specific transcriptional enhancer
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
DE69434860T2 (de) 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
EP1637608B1 (en) 1993-10-25 2009-07-22 CANJI, Inc. Recombinant adenoviral vector and methods of use
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6027721A (en) 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
US5952190A (en) 1996-10-04 1999-09-14 Fanconi Anemia Research Fund, Inc. cDNA for fanconi anemia complementation group A
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US20020065236A1 (en) 1998-09-09 2002-05-30 Yew Nelson S. CpG reduced plasmids and viral vectors
US7994278B1 (en) 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
AU770867B2 (en) 1999-08-13 2004-03-04 Fumie Sato Prostaglandin derivatives
ATE351916T1 (de) 1999-10-12 2007-02-15 Pasteur Institut Lentivirale triplex-dns, und vektoren und rekombinante zellen, die lentivirale triplex-dns enthalten
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
AU2001263006A1 (en) 2000-05-18 2001-11-26 Hyseq, Inc. Novel nucleic acids and polypeptides
US6627442B1 (en) 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
GB0024550D0 (https=) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
EP1412493B1 (en) 2001-08-02 2011-10-05 Institut Clayton De La Recherche Methods and compositions relating to improved lentiviral vector production systems
EP1438075A4 (en) 2001-10-02 2006-04-19 Inst Clayton De La Rech METHOD AND COMPOSITIONS ASSOCIATED WITH LENTIVIRAL VECTORS WITH LIMITED EXPRESSION AND ITS APPLICATIONS
WO2003088910A2 (en) 2002-04-15 2003-10-30 Rigel Pharmaceuticals, Inc. Methods of assaying for cell cycle modulators
NZ536899A (en) 2002-05-02 2008-04-30 Univ Rochester Vectors having both isoforms of beta-hexosaminidase
WO2004094642A2 (en) 2003-04-24 2004-11-04 Fondazione Centro San Raffaele Del Monte Tabor Lentiviral vectors carrying synthetic bi-directional promoters and uses thereof
JP2007054069A (ja) 2005-08-24 2007-03-08 Medizinische Hochschule Hannover 自己不活性化レトロウイルスベクター
BE1016793A4 (fr) 2005-10-04 2007-06-05 Artelis Procede de culture de cellules et dispositif permettant sa mise en oeuvre.
US8324367B2 (en) 2006-11-03 2012-12-04 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
WO2008136670A2 (en) 2007-05-02 2008-11-13 Erasmus University Medical Center Rotterdam Improved methods and means for lentiviral gene delivery
EP2152889B1 (en) 2007-05-29 2017-03-15 Nature Technology Corporation Vectors and methods for genetic immunization
WO2009072003A2 (en) 2007-12-07 2009-06-11 Miltenyi Biotec Gmbh Sample processing system and methods
DE102008063606A1 (de) 2008-12-18 2010-06-24 Eufets Ag Ein-Vektor Tet-System und dessen Verwendung
AU2010241864B2 (en) 2009-04-30 2014-02-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
DE102009021592A1 (de) 2009-05-15 2010-11-18 Medizinische Hochschule Hannover ASLV-Vektorsystem
CA2763482A1 (en) 2009-05-27 2010-12-02 The Salk Institute For Biological Studies Generation of genetically corrected disease-free induced pluripotent stem cells
US8728730B2 (en) 2009-09-03 2014-05-20 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
US20120283318A1 (en) 2009-10-05 2012-11-08 Mei Ya-Fang Replicating viral vectors for gene therapy
RU2638802C2 (ru) 2011-05-16 2017-12-15 Джензим Корпорейшн Применение антагонистов cxcr4
DK3763820T3 (da) 2012-02-29 2022-02-07 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Retroviral transduktion ved hjælp af poloxamerer
KR102530118B1 (ko) 2012-07-25 2023-05-08 더 브로드 인스티튜트, 인코퍼레이티드 유도 ｄｎａ 결합 단백질 및 게놈 교란 도구 및 이의 적용
SG11201504219QA (en) 2012-12-11 2015-06-29 Pall Technology Uk Ltd Recipient for cell cultivation
AU2013359262C1 (en) 2012-12-12 2021-05-13 Massachusetts Institute Of Technology CRISPR-Cas component systems, methods and compositions for sequence manipulation
US20160194660A1 (en) 2012-12-21 2016-07-07 Merck Sharp & Dohme Corp. Expression vectors for recombinant protein production in mammalian cells
EP2792742A1 (en) 2013-04-17 2014-10-22 Universitätsklinikum Hamburg-Eppendorf (UKE) Gene-therapy vectors for treating cardiomyopathy
CN104419683A (zh) * 2013-09-10 2015-03-18 中国科学院生物物理研究所 制备范可尼贫血症患者自体诱导多能干细胞的方法及其应用
GB201318347D0 (en) 2013-10-16 2013-11-27 Ucl Business Plc Retroviral vectors
WO2015073922A2 (en) 2013-11-15 2015-05-21 Northwestern University Inhibition of oxidative stress in atrial fibrillation
CN107405411A (zh) 2014-05-01 2017-11-28 华盛顿大学 使用腺病毒载体的体内基因改造
EP3152221A4 (en) 2014-05-20 2018-01-24 Regents of the University of Minnesota Method for editing a genetic sequence
US11030531B2 (en) * 2014-06-06 2021-06-08 Trustees Of Boston University DNA recombinase circuits for logical control of gene expression
GB201417042D0 (en) 2014-09-29 2014-11-12 Fkd Therapies Oy Method
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
MA41506A (fr) 2015-02-13 2017-12-19 Takeda Vaccines Inc Procédés de production de virus pour produire des vaccins
CN107635575A (zh) 2015-03-10 2018-01-26 纽约市哥伦比亚大学理事会 重组glut1腺相关病毒载体构建体以及用于恢复glut1表达的相关方法
WO2016183593A2 (en) 2015-05-14 2016-11-17 The Regents Of The University Of California Prenatal therapy
WO2017083750A1 (en) 2015-11-11 2017-05-18 Intrexon Corporation Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies
DK3405215T3 (da) 2016-01-19 2022-09-19 Univ California Fremgangsmåder til behandling af danon-sygdom og andre autofagilidelser
WO2017136536A1 (en) 2016-02-02 2017-08-10 University Of Massachusetts Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
WO2017139576A1 (en) 2016-02-12 2017-08-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
RS67367B1 (sr) 2016-04-14 2025-11-28 Ferring Ventures Ltd Bioreaktor sa fiksiranim slojem sa pumpom/sistemom creva sa konstantnim protokom
CA3021572A1 (en) * 2016-04-20 2017-10-26 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Compositions and methods for enhanced gene expression of pklr
US20220323612A1 (en) 2016-06-13 2022-10-13 Bluebird Bio, Inc. Gene therapy of neuronal ceroid lipofuscinoses
EP3471743B1 (en) 2016-06-17 2025-08-06 Fred Hutchinson Cancer Center Strategies to assess and/or produce cell populations with predictive engraftment potential
KR20190088554A (ko) 2016-12-06 2019-07-26 블루버드 바이오, 인코포레이티드. Ii형 점액다당류증에 대한 유전자 요법
KR20190089988A (ko) 2016-12-06 2019-07-31 블루버드 바이오, 인코포레이티드. I형 점액다당류증에 대한 유전자 요법
US20180326022A1 (en) 2017-04-21 2018-11-15 The Trustees Of The University Of Pennsylvania Compositions and methods for improving heart function and treating heart failure
US20200199534A1 (en) 2017-04-27 2020-06-25 Fred Hutchinson Cancer Research Center Therapeutic formulations containing cd34+ stem cells derived from negative selection
EP3697452A4 (en) 2017-10-16 2021-11-24 Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, O.A., M.P. LENTIVIRAL VECTORS FOR ADMINISTRATION OF PKLR TO TREAT PYRUVATE KINASE DEFECTS
BR112020020841A2 (pt) 2018-04-11 2021-01-19 Fundacion Para La Investigacion Biomedica Del Hospital Infantil Universitario Nino Jesus Composições e métodos para transplante de célulastronco
CA3096293A1 (en) 2018-04-27 2019-10-31 Rocket Pharmaceuticals, Ltd. Gene therapy for cns degeneration
WO2020014523A1 (en) 2018-07-12 2020-01-16 Rocket Pharmaceuticals, Ltd. Gene therapy vectors for treatment of danon disease
KR20210046004A (ko) 2018-07-30 2021-04-27 센트로 데 인베스띠가씨오네스 에너제티까스 메디오암비엔딸레스 와이 테크놀로지까스, 오.에이., 엠.피. 조혈 세포의 유전자 변형 방법
JP2021533831A (ja) 2018-08-16 2021-12-09 スペースクラフト セブン リミテッド ライアビリティ カンパニー ウイルスベクターのための生成方法
AU2020221842A1 (en) 2019-02-12 2021-08-12 Spacecraft Seven, Llc Gene therapy vectors for treatment of Danon Disease
CN113994008A (zh) 2019-05-23 2022-01-28 太空飞船七有限责任公司 用于婴儿恶性骨硬化病的基因治疗载体
JP2023535121A (ja) 2020-05-20 2023-08-16 スペースクラフト セブン リミテッド ライアビリティ カンパニー 操作されたパーキン及びその使用
WO2022017630A1 (en) 2020-07-23 2022-01-27 Ucl Business Ltd GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF
BR112023001336A2 (pt) 2020-08-05 2023-02-14 Spacecraft Seven Llc Terapia gênica de csrp3 (proteína 3 rica em cisteína e glicina)
AU2021321412A1 (en) 2020-08-05 2023-04-06 Spacecraft Seven, Llc Adeno-associated viral vector for GLUT1 expression and uses thereof
JP2023538519A (ja) 2020-08-07 2023-09-08 スペースクラフト セブン リミテッド ライアビリティ カンパニー Ａａｖベクターを使用したプラコフィリン－２（ｐｋｐ２）遺伝子治療
CA3201247A1 (en) 2020-12-07 2022-06-16 Gaurav Shah Treatment of danon disease
WO2023108029A2 (en) 2021-12-08 2023-06-15 Spacecraft Seven, Llc Junctophilin-2 (jph2) gene therapy using aav vector
WO2023108129A1 (en) 2021-12-10 2023-06-15 Spacecraft Seven, Llc Troponin c (tnnc1) gene therapy using aav vector
US20250135040A1 (en) 2022-02-08 2025-05-01 Spacecraft Seven, Llc Adeno-associated viral vector for glut1 expression and uses thereof
KR20250012749A (ko) 2022-04-22 2025-01-24 스페이스크래프트 세븐, 엘엘씨 Aav 벡터를 사용한 b-세포 림프종 2-관련 안타노겐 3(bag3) 유전자 요법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016118780A1 (en) 2015-01-21 2016-07-28 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
WO2018049273A1 (en) 2016-09-08 2018-03-15 Centro De Investigaciones Energeticas Medioambientales Y Tecnologicas Gene therapy for patients with fanconi anemia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Blood, (2017), 130, [suppl.1], Article.2451<DOI:10.1182/blood.V130.Suppl_1.2451.2451>
Stem Cells Dev., (2016), 25, [20], p.1591-1603

Also Published As

Publication number Publication date
AU2026200325A1 (en) 2026-04-09
IL277878A (en) 2020-11-30
WO2019200167A1 (en) 2019-10-17
MX2020010718A (es) 2021-01-20
SG11202008400SA (en) 2020-09-29
JP2025004171A (ja) 2025-01-14
RU2020129103A (ru) 2022-03-03
US12539316B2 (en) 2026-02-03
JP2021521180A (ja) 2021-08-26
CN112153973A (zh) 2020-12-29
BR112020020841A2 (pt) 2021-01-19
KR20210003738A (ko) 2021-01-12
IL307996A (en) 2023-12-01
CA3093708A1 (en) 2019-10-17
AU2019252662A1 (en) 2020-09-24
EP3773636A1 (en) 2021-02-17
US20210154237A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
JP7576754B2 (ja) 幹細胞移植のための組成物および方法
JP7664829B2 (ja) 造血細胞の遺伝子改変のための方法
JP6734283B2 (ja) 遺伝子治療用ポイントオブケア及び／又はポータブルプラットフォーム
JP7403461B2 (ja) ピルビン酸キナーゼ欠損症を治療するためのｐｋｌｒ送達用レンチウイルスベクター
JP7430202B2 (ja) プラスミドの組合せおよび改変免疫細胞の調製におけるその適用
US20190203225A1 (en) Gene therapy for patients with fanconi anemia
CN114746546B (zh) 工程化红细胞用于治疗痛风和高尿酸血症
CN1856506A (zh) 向哺乳动物中移植淋巴造血细胞的方法
JP7766110B2 (ja) レンチウイルスベクターおよびその使用
RU2824194C2 (ru) Способы генной модификации гемопоэтических клеток
US20240293466A1 (en) Differential cxcr4 expression on hematopoietic progenitor cells versus stem cells directs homing and long-term engraftment
RU2773358C2 (ru) Композиции и способы усиления экспрессии гена pklr
JP2024516459A (ja) 遺伝子治療のための新規プロモータ配列

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210113

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230118

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231228

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240528

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240829

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240925

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241015

R150 Certificate of patent or registration of utility model

Ref document number: 7576754

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150